Blog

PSMA PET-CT Medicare Rebate

As of 1 July 2022, Medicare rebates are available for patients suffering from prostate cancer. Medicare will now cover the cost of whole body PSMA PET-CT scans for initial staging of prostate cancer, as well as restaging for prostate cancer recurrence. More specific information regarding these Medicare changes is available from Medicare. Qscan is a […]

Dr Hal Rice named Gold Coast Australian of the Year

One of our excellent doctors, Hal Rice, has been named Gold Coast Australian of the Year from a very prestigious panel of finalists. Hal is an incredible doctor, with achievements as a neurointerventionalist in the public and private systems. He is one of Qscan Queensland’s founding partners and established the renowned Neurointerventional Department at the […]

Fluorine-18 (F-18) PSMA PET-CT scans

PSMA PET-CT scans are important in the detection and staging of prostate cancer. In Australia, the most commonly used tracer for PSMA PET-CT scans is Gallium-68 (Ga-68). However, Qscan Group uses Fluorine-18 (F-18), a tracer developed by Professor Martin Pomper, director of nuclear medicine and imaging at the Johns Hopkins University School of Medicine.   Benefits […]

New PET-CT using FET

FET PET-CT is a scan that can detect brain tumours – both primary and metastatic. FET PET-CT is indicated in the use of imaging of brain metastases as follows Detection of viable tumour tissue; Radiolabelled amino acid imaging is superior to FDG PET, CT and MRI for differentiation of viable tumour tissue from treatment induced […]

Obstetric Scanning: The role of ultrasound in first trimester screening

Obstetric scanning plays an important role in first trimester screening. First trimester screening checks that a baby is developing as expected, determines the number of fetuses and estimates gestational time. Obstetric ultrasound and Non-Invasive Perinatal Testing (NIPT) Cell-free fetal DNA (cffDNA) is fetal DNA that circulates through the maternal blood. cffDNA testing is non-invasive and [...]

New International Trial Evidence supports Lutetium Radionuclide Therapy for Prostate Cancer, available at Qscan

Lutetium Radionuclide Therapy for Prostate Cancer is now supported by Randomized Multicentre Phase 3 Data. Qscan provides Lutetium Rx supported by RCT data and international trial protocols individualized to your patient. Emerging current Rx indications: Upfront Lu Rx at emergence of castrate resistance in combination with other agents prior to chemotherapy Node positive patients with […]

the latest

From the Blog

Our Associations

Contact Qscan